Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT07248280

Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients

Led by Centre hospitalier de l'Université de Montréal (CHUM) · Updated on 2026-03-03

260

Participants Needed

1

Research Sites

44 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Postoperative nausea and vomiting (PONV) are a frequent and debilitating complications after surgery, affecting up to 80% of patients at high risk in the absence of prophylaxis. Despite the rigorous application of the recommendations from the American Society of Anesthesiologists (ASA) at CHUM, a recent local study reveals a prevalence of 25% PONV at home after outpatient surgery. However, the therapeutic options at home remain limited. This study aims to evaluate if the addition of 40 mg aprepitant to a multimodal strategy for preventing PONV improves clinical outcomes in high-risk patients undergoing outpatient surgery.

CONDITIONS

Official Title

Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 years and over requiring outpatient surgery
  • High risk of postoperative nausea and vomiting with at least 3 Apfel score factors (female sex; non-smoker; history of postoperative nausea or vomiting or motion sickness; expected opioid use after surgery)
Not Eligible

You will not qualify if you...

  • Refusal or inability to give consent
  • Known or suspected allergy to aprepitant (Emend)
  • Use of medications interacting with aprepitant via cytochrome CYP3A4 (pimozide, terfenadine, astemizole, comtadin, or cisapride)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Centre hospitalier de l'Université de Montréal (CHUM)

Montreal, Quebec, Canada, H2X 0A9

Actively Recruiting

Loading map...

Research Team

M

Maxim Roy, MD, FRCPC

CONTACT

V

Vicky Thiffault, BSN

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients | DecenTrialz